Medlab Clinical - NanaBis development centre stage in 2023
As Medlab Clinical moves into 2023, the expected commencement of a Phase III trial for NanaBis (the company’s cannabinoid based analgesic therapy)...
288 Views
Medlab Clinical - Encouraging real-world data to support NanaBis
Medlab Clinical has announced positive interim data from its real-world evidence study for NanaBis (Medcare observational study). The 12-month...
110 Views
Medlab Clinical - Moving closer to the Nasdaq IPO
Medlab Clinical moves a step closer to realising its plans for a secondary listing on the Nasdaq following filing of the IPO registration statement...
674 Views
Medlab Clinical - Progressing on multiple fronts
Medlab Clinical has announced that it has cleared the Securities Exchange Commission’s (SEC’s) comments on its Nasdaq listing and is now preparing...
681 Views
Medlab Clinical - UK compassionate use for alternative to opioids
Medlab Clinical has announced that it has received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for its lead...
689 Views